Clinical Trial Search

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants

Primary: Enrollment (150 HIV-infected and 50 HIV-uninfected Pregnant Women Within One Year, With a Minimum of 20 of These Women Having HIV/ZIKV Co-infection by Their End of…

Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) — 5; 2; 2; 291 Participants

Primary: Percentage of Participants With Solicited Local Injection Site Reactions by Severity Within 7 Days After Dose 1 of PIZV or Placebo — 13.3; 30.0; 32.3; 38.7 percentage of…

Primary: Number of Participants With Serious Adverse Events From Day 0 Through Week 60 — 0; 0 participants

Primary: Number of Participants With Solicited Local and General Adverse Events (AEs) — 10; 5; 8; 5 Participants

Primary: Number of Subjects With Adverse Events. — 12; 8; 0; 0 participants

Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) — 86; 164; 183; 163 Participants

Primary: Number of Participants With Adherence to Pediatric Zika Care — 14; 15 Participants

Primary: Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for All Participants — 15; 22; 10; 18 Participants

Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination — 0; 0; 0; 1 Participants

Primary: Percentage of Participants Who Experienced an Adverse Event (AE) up to Day 56 — 92.9; 92.9; 91.7; 62.5 Percentage of Participants — p== 0.2003

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants

Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants

Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants

Primary: AEs Grade 3 or Higher — 0.44; 0.65; 0.63 adverse events

Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants

Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants

Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects

Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants

Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml

Primary: Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade — 7; 8; 10; 8 Participants

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection — 136; 161; 58; 37 Participants

Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells

Primary: Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically — 213; 209; 151; 146 Participants

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…